FDA Pharmacy Compounding Advisory Committee (PCAC) — meeting of July 23–24, 2026. Each vote decides whether the committee recommends adding the peptide to the 503A bulk drug substances list (whether compounding pharmacies may make it). A majority Yes = recommended.
Every committee member ranked by how often they backed compounding. Support score = share of decisive votes cast as Yes (abstentions and absences excluded). Y = Yes · N = No · A = Abstain · – = not present.
| # | BPC-fb | BPC-ac | TB-500 | MOTS-c | DSIP | EPI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gabriel Alizaidy, MDPro | Y | Y | Y | Y | Y | Y | 6 | 100% | |||
| 2 | Joshua Starbuck, MDPro | Y | Y | Y | Y | Y | Y | 6 | 100% | |||
| 3 | Kris Wusterhausen, DOPro | Y | Y | Y | Y | Y | Y | 6 | 100% | |||
| 4 | Melissa Loseke, DOPro | Y | Y | Y | Y | Y | Y | 6 | 100% | |||
| 5 | Sen. Bobby HarshbargerPro | Y | Y | Y | Y | Y | Y | 6 | 100% | |||
| 6 | Asare Christian, MDPro | Y | Y | Y | A | Y | Y | 5 | 1 | 100% | ||
| 7 | Haleem Mohammed, MDPro | Y | Y | Y | Y | – | – | 4 | 2 | 100% | ||
| 8 | David Pope, PharmDSwing | Y | Y | Y | Y | N | Y | 5 | 1 | 83% | ||
| 9 | Kevin Zacharoff, MDAnti | – | – | – | – | N | – | 1 | 5 | 0% | ||
| 10 | Maral Kibarian Skelsey, MDAnti | – | – | N | – | – | – | 1 | 5 | 0% | ||
| 11 | Brian Lee, MDAnti | N | N | – | – | – | – | 2 | 4 | 0% | ||
| 12 | Elizabeth Rebello, RPhAnti | N | N | N | N | N | – | 5 | 1 | 0% | ||
| 13 | Brian Serumaga, PhDAnti | N | N | N | N | N | N | 6 | 0% | |||
| 14 | Josh Mailman, MBAAnti | N | N | N | N | N | N | 6 | 0% | |||
| 15 | Todd Durham, PhDAnti | N | N | N | N | N | N | 6 | 0% | |||
| 16 | William Zamboni, PharmDAnti | N | N | N | N | N | N | 6 | 0% | |||
| 17 | Timothy Fensky, RPhAbstainer | A | A | A | A | A | A | 6 | — |